

Cover Story
Conversation with The Cancer Letter
In an in-depth interview with The Cancer Letter, an FDA official clarified the agency's criteria for approval of drugs that target PD-1 and PD-L1.
Free
By Matthew Bin Han Ong
By Matthew Bin Han Ong
In Brief


Funding Opportunities
Drugs & Targets


Trending Stories
- Mt. Sinai forms committee to probe Epstein links to breast center founder Eva Dubin, other faculty members
- NCI slated to get a $9 million raise as Trump’s budget proposes about 10% cut for NIH
- Lawsuits brought against Tempus AI raise more questions than answers about DNA privacy in the AI era
- Trump imposes up to 100% tariff on some brand name pharmaceutical companies
- Michael Bishop, Nobel-winning cancer researcher, dies at 90
- Gonzalez-Angulo Found Guilty In MD Anderson Poisoning Case













